Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma

NCT07535840 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.

NCT NCT07535840
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07535840 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma
Lead sponsor
Tongji Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
May 31, 2026
Completion date
June 30, 2027
Enrollment
25 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hcc - hepatocellular carcinoma, resistant cancer, tp53 gene mutation, unresectable